GE Healthcare
Trial Pipeline
GSI Cardiac on Revolution Apex - US
NCT06702917
Next Generation CT System
NCT06769594
Maternal Fetal Device Performance Twins
NCT06835647
Clinical Feasibility and Evaluation of Silicon Photon Counting CT
NCT05838482
Clinical Data Collection and Evaluation of ECG-Less Cardiac CT
NCT05949138
Study to Determine Safety and Dosage of OPTISON in Pediatric Participants
NCT03740997
Patient-Assisted Compression in 3D - Impact on Image Quality and Workflow
NCT03456427
Performance of the Monica Novii Wireless Patch System in Pre-term Labor
NCT03057275
Clinical Evaluation Of MP26 Features in Adults
NCT02927327
A Case Collection Study for Digital Breast Tomosynthesis (DBT) Using the Senographe Essential
NCT01885143
Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.
NCT01936649
Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)
NCT01952678
Clinical Evaluation for General Electric (GE) CT System
NCT01909180
Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
NCT01475097
Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis
NCT01376089
A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System
NCT01076296
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
NCT01028053
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
NCT00918281
Comparative Study of Phototherapy for Hyperbilirubinemia
NCT00635375
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 4 |
What the Pipeline for GE Healthcare Shows
According to the ClinicalTrials.gov registry, GE Healthcare is linked to 19 US clinical trials across every stage of research activity. Of those, 4 studies are currently recruiting — about 21% of the sponsor's indexed portfolio — and 15 are already marked complete, representing roughly 79% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for GE Healthcare reports 5 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for GE Healthcare is Breast Cancer with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.